Tag:

Valeant

Latest Headlines

Latest Headlines

With 77 layoffs, Valeant gets to work squeezing costs from Dendreon

It's no secret that when serial acquirer and cost-cutting enthusiast Valeant takes over a company, layoffs are on the way. And for Dendreon, the bankrupt Seattle biotech whose assets the Canadian snatched up last month, they've already begun.

Valeant welcomes Dendreon into the fold with a 77-job shearing

It's no secret that when serial acquirer and cost-cutting enthusiast Valeant takes over a company, layoffs are on the way. And for Dendreon, the bankrupt Seattle biotech whose assets the Canadian snatched up last month, they've already begun.

Valeant starts carving up what remains of Dendreon, axing 77 staffers

Valeant has wasted no time in getting down to brass tacks at its newly acquired subsidiary Dendreon. The company notified the state of Washington that it is laying off 77 staffers from the biotech's steadily shrinking roster of employees, according to a report from the Seattle Times.

Valeant touts PhII Provenge data following Dendreon buy

Valeant only just picked up Provenge and other assets from bankrupt Dendreon, but it's already trumpeting positive preliminary data for the flailing cancer vaccine. On Wednesday, it announced Phase II results showing that the immune response from Provenge continues two years after biochemically recurrent prostate cancer patients complete treatment.

Valeant to keep specialty Salix reps, but it's eyeing primary care for potential cuts

Salix may have just agreed to sell itself to Valeant, a company known for squeezing every penny out of its acquisitions. But never fear, specialty sales reps: CEO J. Michael Pearson says you're safe.

Valeant's low Salix price may leave room for other bids

Valeant may have inked a pact to buy Salix Pharmaceuticals for more than $10 billion. But that doesn't necessarily mean rival bids aren't on the way.

With Salix buy, Valeant bets $10B on GI market growth

It didn't take long for serial acquirer Valeant to jump back into the dealmaking saddle after failing to snag Allergan last year. Now, the Canadian pharma has inked its second agreement of the month--a $10.1 billion pickup of North Carolina's Salix Pharmaceuticals that will ring in as its largest deal ever.

Valeant closing in on $160-per-share Salix deal: Reuters

There are reportedly at least three horses in the race to buy Salix Pharmaceuticals, but according to Reuters ' sources, serial acquirer Valeant has the lead.

Shire and Valeant are reportedly eyeing $10B bids for Salix

Salix Pharmaceuticals, moving on from an embarrassing inventory scandal, is reportedly headed for a bidding war between two larger companies with diametric approaches to the business of developing drugs.

UPDATED: Valeant, Shire prep Salix bids

Earlier this month, rumors started swirling that Valeant was talking with its advisers about a potential bid for North Carolina's Salix Pharmaceuticals. Now, it's reportedly one step closer to making that happen--but it may not be alone.